Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PillCam equals conventional endoscopy for GERD (gastro-esophagous reflex disease)

This article was originally published in Clinica

Executive Summary

Given Imaging says that further evidence is now available to show that its ingestible oesophageal capsule endoscopy (ECE), PillCam, is as effective as conventional endoscopy in detecting abnormalities associated with gastro-esophagous reflex disease (GERD). The data were presented at this month's American College of Gastroenterology meeting in Orlando and follow last month's FDA 510(k) clearance of the device for use in oesophageal imaging. A variant of the technology, the PillCam SB, is already available worldwide for imaging the small intestine.

You may also be interested in...



COVID-19 May Delay WHO’s Prequalification Of Devices, IVDs

Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.

COVID-19 May Delay WHO’s Prequalification Of Drugs, Devices, IVDs

Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.

Celltrion Makes Progress On Coronavirus Treatment

Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

Topics

UsernamePublicRestriction

Register

MT060080

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel